---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-285498"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2026-06-26T20:15:14+00:00"
generated_at: "2026-06-26T20:18:57.322722+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atara CAO to depart July 17; Kevin Sarney appointed interim CFO

## Summary
- Yanina Grant-Huerta, Chief Accounting Officer, notified on June 22 that employment ends July 17, 2026.
- Board appointed Kevin G. Sarney (CRCFO) as interim CFO effective June 26; he serves as principal financial and accounting officer.
- Sarney has over 25 years life science finance experience, previously at PwC and executive roles at public/private life science companies.
- Sarney paid through CRCFO consulting; company pays hourly rate; no direct compensation from company.
- Consulting agreement terminable on 30 days notice; Sarney enters standard indemnification.

## SEC filing metadata
- accession: 0001193125-26-285498
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2026-06-26T20:15:14+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312526285498/0001193125-26-285498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312526285498/atra-20260622.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-285498
- JSON: https://secwatch.observer/filing/0001193125-26-285498.json
- Plain text: https://secwatch.observer/filing/0001193125-26-285498.txt

## Key facts
- Executive change
  Kevin G. Sarney was appointed as interim chief financial officer at Atara Biotherapeutics, Inc..
  - Action: appointed
  - Role: interim chief financial officer
  source text: On June 26, 2026, the Company’s Board of Directors appointed Kevin G. Sarney, Life Science Practice Leader at Charles River CFO, Inc. (“CRCFO”), as interim chief financial officer, effective as of June 26, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312526285498/0001193125-26-285498-index.htm
- Executive change
  Yanina Grant-Huerta departed as Chief Accounting Officer at Atara Biotherapeutics, Inc..
  - Action: notified
  - Role: Chief Accounting Officer
  source text: On June 22, 2026, Atara Biotherapeutics, Inc. (the “Company”) notified Yanina Grant-Huerta, the Company’s Chief Accounting Officer, that her employment with the Company would end effective July 17, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312526285498/0001193125-26-285498-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.